Nevertheless, with expanding clinical adoption of PARP inhibitors in first-line maintenance regimens for ovarian cancer, the emergence of acquired resistance has become a critical clinical barrier requiring urgent resolution. The gene discussed is PARP1; the disease is ovarian carcinoma.